The President of the European Council, Charles Michel, expressed his confidence in “transparency” in the pharmaceutical companies about the reasons for the retrospectives in the vacancies against the covid-19 announced by AstraZeneca and Pfizer.
“What we call these companies, is a transparent dialogue” verklaar Charles Michel in various French media.
“It is a matter (…) that we should respect the contracts that were made by the pharmaceutical companies” affirmed the President of the Council, who represents the 27 Member States of the EU.
“When Pfizer announces weekly changes, if we react with the company and finally the announcements of weekly changes will be reduced “says Michel.
Charles Michel was shown compelling obstruction with industrial failures and the “obstacles” that could confront laboratories, such as the problems of “the prime minister of materials as his necessaries”.
Three of the retreats announced by Pfizer in the holiday vouchers against the covid-19, an announcement similar to AstraZeneca’s fourth generation surveyed and enforced in Europe, which unlocks a counter-carrier ahead of the appearance of newer coronavirus variants.
The European Union has signed a total of six pharmaceutical contracts and is in negotiations with others, for a total of 2500 million of potential doses.